A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

NCT00662675 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Exocrine Pancreatic Insufficiency
Steatorrhea
Malabsorption Syndromes
Cystic Fibrosis

Interventions

DRUG: Pancrease MT 10.5, or MT 21
DRUG: Placebo for Pancrease MT 10.5 or MT 21

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.